# Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT04047797** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Ixazomib Citrate
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT04047797
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-28
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-04-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Administratively Complete 75%\<Participants
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047797, "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04047797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*